Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Caleres Shares Face Mounting Pressure as Analyst Concerns Deepen

Dieter Jaworski by Dieter Jaworski
October 26, 2025
in Analysis, Consumer & Luxury, Earnings
0
Caleres Stock
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

The downward trajectory for Caleres shares shows no signs of abating. The footwear company’s stock declined another 2.0 percent in recent trading, closing at $12.57. This continued weakness follows the latest confirmation of a “Sell” rating from Weiss Ratings and reflects persistent investor anxiety following disappointing quarterly results.

Multiple Analyst Warnings Signal Trouble

Market experts are sounding alarms about Caleres’s deteriorating position. Two prominent research firms have issued clear sell recommendations in recent weeks. Weiss Ratings reaffirmed its “Sell (D+)” assessment on Saturday, while Zacks Research had already downgraded the stock to “Strong Sell” in late August. The consensus from analysts is unmistakable: investors should avoid this equity.

The financial performance tells a concerning story. During the second quarter, Caleres fell significantly short of profit expectations. Instead of the anticipated $0.51 per share, the company reported earnings of just $0.35 per share—a substantial $0.16 miss. Although revenue of $658.52 million slightly exceeded projections, this still represented a 3.6 percent decrease compared to the same period last year.

Structural Challenges Compound Quarterly Weakness

Several fundamental issues are driving the persistent decline:

Should investors sell immediately? Or is it worth buying Caleres?

  • The average price target sits at just $14.00 alongside sell recommendations
  • S&P downgraded the company’s rating to ‘BB-‘ due to increased debt levels
  • The $120.2 million Stuart Weitzman acquisition continues to weigh on the balance sheet
  • Management’s suspension of full-year guidance serves as a red flag for investors

The current weakness period comes as no surprise to attentive market observers. The September release of second-quarter figures initially triggered a selling frenzy, with shares plunging 11.27 percent, followed by an additional 16.59 percent drop in pre-market trading. The company’s underlying operational challenges appear to have persisted since that time.

December Quarterly Report Pivotal for Recovery Hopes

All eyes now turn to the next quarterly results scheduled for early December. The critical question remains whether Caleres can stage a recovery or faces further declines. Structural problems—from elevated debt burdens to weak operational performance—provide little room for optimism.

The footwear manufacturer is navigating challenging market conditions. While proposed annual cost savings of $15 million and supply chain diversification efforts could theoretically provide support, the decisive factor remains whether these measures will prove sufficient to reverse the negative trend.

Ad

Caleres Stock: Buy or Sell?! New Caleres Analysis from February 7 delivers the answer:

The latest Caleres figures speak for themselves: Urgent action needed for Caleres investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Caleres: Buy or sell? Read more here...

Tags: Caleres
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Boston Omaha Stock
Analysis

Investors Await March Report for Boston Omaha’s Strategic Direction

February 7, 2026
Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Next Post
Workiva Stock

Workiva Shares: Conflicting Signals Create Investor Dilemma

Arbor Realty Stock

Critical Earnings Report Looms for Arbor Realty Trust

Soleno Therapeut. Stock

Soleno Therapeutics Nears Critical Financial Milestone

Recommended

XRP Stock

XRP Faces Resistance as Rally Attempt Falters

2 months ago
Insurance company Stock Bull Market

Analyst Expresses Optimism Towards Travelers Companies and Allstate

2 years ago
Rheinmetall Stock

German Defense Giant Rheinmetall Poised for Major Air Defense Contract

4 months ago
Finance_Capitalistic

Top Stock Picks and Performance Analysis on CNBCs Halftime Report Final Trades

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Camping World’s New Leadership Faces First Major Test

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Trending

Boston Omaha Stock
Analysis

Investors Await March Report for Boston Omaha’s Strategic Direction

by SiterGedge
February 7, 2026
0

With no recent corporate announcements influencing its share price, market attention has shifted decisively to the upcoming...

Universal Insurance Stock

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

February 7, 2026
Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Investors Await March Report for Boston Omaha’s Strategic Direction
  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com